August 14, 2025Health Economics ReviewOpen Access

Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand

View Full Paper

Ask AI

Bookmark

Authors

DLDanlan LianZhongshan Hospital of Xiamen University YSY. C. Suo RGRuoyan GaiNagasaki University

Discussion

Member takes

Implication

Cost-effectiveness analysis finds renal denervation reduces cardiovascular events in hypertension patients across three countries, highlighting regional affordability variations.

Key Points

Renal denervation resulted in a 30.61% reduction in cardiovascular, cerebral, and renal events compared to antihypertensives alone.
The incremental cost-effectiveness ratio for the RDN regimen was $3,451 per QALY in Japan and $19,049 per QALY in China.
A Markov decision-analytic model simulated long-term outcomes and costs among patients over 30 years.
Cost-effectiveness varies across countries, indicating the need for tailored pricing strategies in different socioeconomic contexts.

Cite This Study

Lian et al. (2025) studied this question.

synapsesocial.com/papers/689fe7904167a9108f7548e4 https://doi.org/10.1186/s13561-025-00669-w

View Full Paper

Ask AI

Bookmark

Implication

Cost-effectiveness analysis finds renal denervation reduces cardiovascular events in hypertension patients across three countries, highlighting regional affordability variations.

Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand

Discussion

Member takes

Implication

Key Points

Cite This Study

Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider